TTOO News and Press, T2 Biosystems Inc. From 02/17/22

T2 Biosystems press release (NASDAQ:TTOO): Q4 GAAP EPS of -$0.07 beats by $0.03. Revenue of $6.98M (-10.3% Y/Y) beats by $1.58M. Shares +5.6%. The company expects FY2022 total revenue of $28M to $31M vs. consensus of $30.75M, including product revenue of $16M to $17M and research and contribu...

LEXINGTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the fourth quarter and full year ended December 31, 2021. Fu...

LEXINGTON, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Norway, Finland, and Türkiye. Under the terms of the agree...

T2 Biosystems (NASDAQ:TTOO) has announced an amendment to its Term Loan Agreement with CRG Servicing. Both the interest-only period and the maturity date by one year from Dec. 31, 2022 to Dec. 31, 2023. No other material amendments were made to the Term Loan Agreement. For further details s...

LEXINGTON, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”). The ...

LEXINGTON, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, Febru...

T2 Biosystems (TTOO -2.0%) said its T2SARS-CoV-2 Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3. T2 Biosystems said to confirm that the T2SARS-CoV-2 Panel would detect the new Omicron subvariants (BA.1, BA.2, and BA.3), the company undertook in silico analysis using genetic s...

LEXINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO),  a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3. According to th...

LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. Recent Highligh...

LEXINGTON, Mass., Jan. 11, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submissi...